血清Hcy/HDL-C比值对急性脑梗死患者溶栓治疗预后的预测价值OA
Predictive value of serum Hcy/HDL-C ratio for the prognosis of thrombolytic therapy in patients with acute cerebral infarction
目的 探讨血清同型半胱氨酸(Hcy)与高密度脂蛋白胆固醇(HDL-C)的比值对急性脑梗死患者静脉溶栓治疗后 3 个月预后的预测价值.方法 回顾性纳入 2019 年 1 月至 2023 年 2 月在商丘市第一人民医院接受静脉溶栓治疗的 150 例急性脑梗死患者作为研究对象.所有患者入院时采集静脉血检测血清 Hcy、HDL-C 水平并计算二者比值,出院后随访 3 个月,采用改良 Rankin 量表(mRS)评估预后,将 mRS 评分≥3 分者纳入预后不良组(n=70),mRS 评分 0~2 分者纳入预后良好组(n=80).比较两组患者的基线临床资料及血清 Hcy、HDL-C、Hcy/HDL-C 比值水平,采用多因素 logistic 回归分析溶栓后预后不良的独立影响因素,绘制受试者工作特征(ROC)曲线评估各指标对预后不良的预测效能.结果 预后不良组患者年龄≥60 岁比例、发病至溶栓时间≥4.5 h 比例、心源性栓塞型脑梗死比例均显著高于预后良好组(均 P<0.01).预后不良组血清 Hcy 水平、Hcy/HDL-C 比值显著高于预后良好组,HDL-C 水平显著低于预后良好组(均 P<0.001).多因素 logistic 回归分析校正年龄、发病至溶栓时间、病因分型后显示,血清 Hcy 水平升高(OR=1.280,95%CI:1.147~1.429,P<0.001)、HDL-C 水平降低(OR=0.004,95%CI:0.000~0.086,P=0.001)、Hcy/HDL-C 比值升高(OR=1.120,95%CI:1.070~1.173,P<0.001)是急性脑梗死患者溶栓后预后不良的独立危险因素.ROC 曲线分析显示,Hcy/HDL-C 比值预测预后不良的曲线下面积(AUC)为 0.844(95%CI:0.780~0.907),最佳截断值为 37.285,灵敏度为 76.2%,特异度为 84.3%,约登指数为 0.605,预测效能优于单独检测Hcy(AUC=0.777)或HDL-C(AUC=0.756).结论 血清Hcy/HDL-C 比值对急性脑梗死患者静脉溶栓治疗后3个月的预后具有良好的预测价值,可作为临床早期识别预后不良高危患者的简便血清学标志物,指导个体化干预方案的制定.
Objective To investigate the predictive value of serum homocysteine(Hcy)/high-density lipoprotein choles-terol(HDL-C)ratio for 3-month prognosis after intravenous thrombolysis therapy in patients with acute cerebral infarction.Methods A total of 150 patients with acute cerebral infarction who received intravenous thrombolysis at the First People's Hospital of Shangqiu from January 2019 to February 2023 were retrospectively enrolled.Venous blood was collected from all patients upon admission to measure serum Hcy and HDL-C levels,and the ratio of the two was calculated.After discharge,patients were followed up for 3 months,and their prognosis was assessed using the modified Rankin Scale(mRS).Patients with mRS scores≥3 were included in poor prognosis group(n=70),while those with mRS scores of 0-2 were included in good prognosis group(n=80).Baseline clinical data and serum levels of Hcy,HDL-C,and Hcy/HDL-C ratio were com-pared between the two groups.Multivariate logistic regression analysis was performed to identify independent risk factors for poor prognosis after thrombolysis.Receiver operating characteristic(ROC)curves were plotted to evaluate the predictive effi-cacy of each indicator for poor prognosis.Results The proportions of patients aged≥60 years,time from onset to thrombol-ysis≥4.5 hours,and cardioembolic stroke were significantly higher in the poor prognosis group than in the good prognosis group(all P<0.01).Compared with the good prognosis group,the poor prognosis group had significantly higher serum Hcy level and Hcy/HDL-C ratio,and significantly lower HDL-C level(all P<0.001).Multivariate logistic regression analysis adjusted for age,time from onset to thrombolysis,and etiological subtype showed that elevated serum Hcy level(OR=1.280,95%CI:1.147-1.429,P<0.001),decreased HDL-C level(OR=0.004,95%CI:0.000-0.086,P=0.001),and elevated Hcy/HDL-C ratio(OR=1.120,95%CI:1.070-1.173,P<0.001)were independent risk factors for poor prognosis in patients with acute cerebral infarction after thrombolysis.ROC curve analysis showed that the area under the curve(AUC)of Hcy/HDL-C ratio for predicting poor prognosis was 0.844(95%CI:0.780-0.907),with an optimal cut-off value of 37.285,sensitivity of 76.2%,specificity of 84.3%,and Youden index of 0.605.The predictive efficacy of Hcy/HDL-C ratio was superior to that of Hcy(AUC=0.777)or HDL-C(AUC=0.756)alone.Conclusion Serum Hcy/HDL-C ratio has good predictive value for 3-month prognosis in patients with acute cerebral infarction after intravenous throm-bolysis.It can be used as a simple serological marker for early clinical identification of high-risk patients with poor prognosis,and guide the development of individualized intervention strategies.
孟杉杉;杨青松
河南省商丘市第一人民医院神经内科,河南 商丘 476000河南省商丘市第一人民医院神经内科,河南 商丘 476000
医药卫生
急性脑梗死静脉溶栓同型半胱氨酸高密度脂蛋白胆固醇Hcy/HDL-C比值预后
acute cerebral infarctionintravenous thrombolysishomocysteine(Hcy)high-density lipoprotein cholester-ol(HDL-C)Hcy/HDL-C ratioprognosis
《右江医学》 2026 (4)
361-367,7
河南省医学科技攻关计划联合共建项目(LHGJ20230989)
评论